356 related articles for article (PubMed ID: 33925949)
41. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.
Fowler D; Nattress C; Navarrete AS; Barisa M; Fisher J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885108
[TBL] [Abstract][Full Text] [Related]
42. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
[TBL] [Abstract][Full Text] [Related]
43. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
44. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
Sullivan PM; Reed SJ; Kalia V; Sarkar S
Front Immunol; 2021; 12():706150. PubMed ID: 34867942
[TBL] [Abstract][Full Text] [Related]
45. Analysis of causes for poor persistence of CAR-T cell therapy
Kong Y; Tang L; You Y; Li Q; Zhu X
Front Immunol; 2023; 14():1063454. PubMed ID: 36761742
[TBL] [Abstract][Full Text] [Related]
46. Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept.
León-Triana O; Pérez-Martínez A; Ramírez-Orellana M; Pérez-García VM
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572301
[TBL] [Abstract][Full Text] [Related]
47. CAR-T Cell Performance: How to Improve Their Persistence?
López-Cantillo G; Urueña C; Camacho BA; Ramírez-Segura C
Front Immunol; 2022; 13():878209. PubMed ID: 35572525
[TBL] [Abstract][Full Text] [Related]
48. Bright future or blind alley? CAR-T cell therapy for solid tumors.
Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
[TBL] [Abstract][Full Text] [Related]
49. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
Antoñana-Vildosola A; Zanetti SR; Palazon A
Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
[TBL] [Abstract][Full Text] [Related]
50. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
51. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
53. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
54. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
55. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
56. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors.
Qin VM; Haynes NM; D'Souza C; Neeson PJ; Zhu JJ
Front Immunol; 2021; 12():813832. PubMed ID: 35095911
[TBL] [Abstract][Full Text] [Related]
57. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
58. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
59. Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies.
Hull CM; Maher J
Expert Opin Drug Discov; 2021 Oct; 16(10):1105-1117. PubMed ID: 34038292
[No Abstract] [Full Text] [Related]
60. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
